Jamie Sin Ying Ho

Dr. Jamie Sin Ying Ho


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JHJamie Sin Ying Ho
Jamie Sin Ying Ho
EJEric Jou
Eric Jou
PKPek Lan Khong
Pek Lan Khong
RFRoger S. Y. Foo
Roger S. Y. Foo
Ching-Hui SiaChing-Hui Sia
Ching-Hui Sia
Heart failure is a clinical syndrome with rising global incidence and poor prognosis despite improvements in medical therapy. There is increasing research interest in epigenetic therapies for heart failure. Pathological cardiac remodelling may be driven by stress-activated cardiac signalling cascades, and emerging research has shown the involvement of epigenetic signals that regulate transcriptional changes leading to heart failure. In this review, we appraise the current evidence for the role of epigenetic modifications in heart failure. These include DNA methylation and histone modifications by methylation, acetylation, phosphorylation, ubiquitination and sumoylation, which are critical processes that establish an epigenetic pattern and translate environmental stress into genetic expression, leading to cardiac remodeling. We summarize the potential epigenetic therapies currently in development, including the limited clinical trials of epigenetic therapies in heart failure. The dynamic changes in the epigenome in the disease process require further elucidation, and so does the impact of this process on the development of therapeutics. Understanding the role of epigenetics in heart failure may pave the way for the identification of novel biomarkers and molecular targets, and facilitate the development of personalized therapies for this important condition.

7 June 2024 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
JKJin Hean Koh
Jin Hean Koh
CLClaire Yi Jia Lim
Claire Yi Jia Lim
LTLucas Tze Peng Tan
Lucas Tze Peng Tan
AMAndrew Makmur
Andrew Makmur
EGEsther Yanxin Gao
Esther Yanxin Gao
Benjamin Yong-Qiang TanBenjamin Yong-Qiang Tan
Benjamin Yong-Qiang Tan

25 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ILIsis Claire ZY Lim
Isis Claire ZY Lim
TYteo yaohao
teo yaohao
JFJun Tao Fang
Jun Tao Fang
YTYao Neng Teo
Yao Neng Teo
JHJamie Sin Ying Ho
Jamie Sin Ying Ho
Benjamin Yong-Qiang TanBenjamin Yong-Qiang Tan
Benjamin Yong-Qiang Tan
Introduction: Patent foramen ovale (PFO) is a potential source of cardiac embolism in cryptogenic ischemic stroke, but it may also be incidental. Right-to-left shunt (RLS) size may predict PFO-related stroke, but results have been controversial. In this cohort study of medically-managed PFO patients with cryptogenic stroke, we aimed to investigate the association of shunt size with recurrent stroke, mortality, newly detected atrial fibrillation (AF), and to identify predictors of recurrent stroke. Methods: Patients with cryptogenic stroke who screened positive for a RLS using a transcranial Doppler bubble study were included. Patients who underwent PFO closure were excluded. Subjects were divided into two groups: small (Spencer Grade 1, 2, or 3; n = 135) and large (Spencer Grade 4 or 5; n = 99) shunts. The primary outcome was risk of recurrent stroke, and the secondary outcomes were all-cause mortality and newly detected AF. Results: The study cohort included 234 cryptogenic stroke patients with medically-managed PFO. The mean age was 50.5 years, and 31.2% were female. The median period of follow-up was 348 (IQR 147-1096) days. The rate of recurrent ischemic stroke was higher in patients with large shunts than in those with small shunts (8.1% vs. 2.2%, p = 0.036). Multivariate analyses revealed that a large shunt was significantly associated with an increased risk of recurrent ischemic stroke [aOR 4.09 (95% CI 1.04–16.0), p = 0.043]. Conclusions: In our cohort of cryptogenic stroke patients with medically managed PFOs, those with large shunts were at a higher risk of recurrent stroke events, independently of RoPE score and left atrium diameter.

RCRyan CH Chee
Ryan CH Chee
NLNorman Huangyu Lin
Norman Huangyu Lin
JHJamie Sin Ying Ho
Jamie Sin Ying Ho
ALAloysius Sheng‑Ting Leow
Aloysius Sheng‑Ting Leow
TLTony Y. W. Li
Tony Y. W. Li
Ching-Hui SiaChing-Hui Sia
Ching-Hui Sia
(1) Background: Little is known about how left ventricular systolic dysfunction (LVSD) affects functional and clinical outcomes in acute ischemic stroke (AIS) patients undergoing thrombolysis; (2) Methods: A retrospective observational study conducted between 2006 and 2018 included 937 consecutive AIS patients undergoing thrombolysis. LVSD was defined as left ventricular ejection fraction (LVEF) < 50%. Univariate and multivariate binary logistic regression analysis was performed for demographic characteristics. Ordinal shift regression was used for functional modified Rankin Scale (mRS) outcome at 3 months. Survival analysis of mortality, heart failure (HF) admission, myocardial infarction (MI) and stroke/transient ischemic attack (TIA) was evaluated with a Cox-proportional hazards model; (3) Results: LVSD patients in comparison with LVEF ≥ 50% patients accounted for 190 and 747 patients, respectively. LVSD patients had more comorbidities including diabetes mellitus (100 (52.6%) vs. 280 (37.5%), p < 0.001), atrial fibrillation (69 (36.3%) vs. 212 (28.4%), p = 0.033), ischemic heart disease (130 (68.4%) vs. 145 (19.4%), p < 0.001) and HF (150 (78.9%) vs. 46 (6.2%), p < 0.001). LVSD was associated with worse functional mRS outcomes at 3 months (adjusted OR 1.41, 95% CI 1.03–1.92, p = 0.030). Survival analysis identified LVSD to significantly predict all-cause mortality (adjusted HR [aHR] 3.38, 95% CI 1.74–6.54, p < 0.001), subsequent HF admission (aHR 4.23, 95% CI 2.17–8.26, p < 0.001) and MI (aHR 2.49, 95% CI 1.44–4.32, p = 0.001). LVSD did not predict recurrent stroke/TIA (aHR 1.15, 95% CI 0.77–1.72, p = 0.496); (4) Conclusions: LVSD in AIS patients undergoing thrombolysis was associated with increased all-cause mortality, subsequent HF admission, subsequent MI and poorer functional outcomes, highlighting a need to optimize LVEF.

3 October 2022 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
TYTiffany T. S. Ye
Tiffany T. S. Ye
QSQi Zhuang Siah
Qi Zhuang Siah
Benjamin Yong-Qiang TanBenjamin Yong-Qiang Tan
Benjamin Yong-Qiang Tan
JHJamie Sin Ying Ho
Jamie Sin Ying Ho
NSNicholas L. X. Syn
Nicholas L. X. Syn
Ching-Hui SiaChing-Hui Sia
Ching-Hui Sia

15 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Benjamin Yong-Qiang TanBenjamin Yong-Qiang Tan
Benjamin Yong-Qiang Tan
JHJamie Sin Ying Ho
Jamie Sin Ying Ho
Andrew Fu Wah HoAndrew Fu Wah Ho
Andrew Fu Wah Ho
PPPin Pin Pek
Pin Pin Pek
ALAloysius Sheng-Ting Leow
Aloysius Sheng-Ting Leow
HZHuili Zheng
Huili Zheng
Acute ischemic strokes (AIS) are closely linked with air pollution, and there is some evidence that traditional cardiovascular risk factors may alter the relationship between air pollution and strokes. We investigated the effect of atrial fibrillation (AF) on the association of AIS with air pollutants. This was a nationwide, population-based, case-only study that included all AIS treated in public healthcare institutions in Singapore from 2009 to 2018. Using multivariable logistic regression, adjusted for time-varying meteorological effects, we examined how AF modified the association between AIS and air pollutant exposure. A total of 51,673 episodes of AIS were included, with 10,722 (20.7%) having AF. The odds of AIS in patients with AF is higher than those without AF for every 1 µg/m3 increase in O3 concentration (adjusted OR [aOR]: 1.005, 95% CI 1.003–1.007) and every 1 mg/m3 increase in CO concentration (aOR: 1.193, 95% CI 1.050–1.356). However, the odds of AIS in patients with AF is lower than those without AF for every 1 µg/m3 increase in SO2 concentration (aOR: 0.993, 95% CI 0.990–0.997). Higher odds of AIS among AF patients as O3− and CO concentrations increase are also observed in patients aged ≥65 years and non-smokers. The results suggest that AF plays an important role in exacerbating the risk of AIS as the levels of O3 and CO increase.